(Q38106805)

29 August 2017

title

Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers (English)

1 reference

29 August 2017

Aditya K Gupta

1

0 references

author name string

Maryse Paquet

series ordinal

2

1 reference

29 August 2017

publication date

1 May 2013

1 reference

Journal of cutaneous medicine and surgery

29 August 2017

published in

1 reference

29 August 2017

volume

17

1 reference

29 August 2017

issue

3

1 reference

29 August 2017

page(s)

173-179

1 reference

Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Management of field change in actinic keratosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Characterization of the interaction of ingenol 3-angelate with protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Proceedings of the First International Conference on PEP005.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005).

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

The spectrum of ocular inflammation caused by euphorbia plant sap.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Ingenol mebutate gel for actinic keratosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2012.12050

21 January 2018

Identifiers

DOI

10.2310/7750.2012.12050

1 reference

29 August 2017

1 reference